Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: NeuroInvestment who wrote (1026)	7/17/1998 10:16:00 AM
From: Ariella	Read Replies (2) \| Respond to of 1491

Dear NeuroInvestment: Am I correct in assuming that the change to 200 mg. from 300 mg. dosage level for the third cohort of Phase II is good? I read it as they believe they have enough good news from first two groups and don't want to take any unnecessary chances with third portion of trial. The idea, after all, is to get into Phase III. But why the note that they might increase number of sites? Are they concerned that the study has too few patients to make real statistical validity? Or just making sure every "i" is dotted, every "t" crossed? Regards, Ariella